Sector
PharmaceuticalsOpen
₹271.15Prev. Close
₹272.6Turnover(Lac.)
₹119.34Day's High
₹286.2Day's Low
₹271.1552 Week's High
₹329.752 Week's Low
₹153.37Book Value
₹16.02Face Value
₹10Mkt Cap (₹ Cr.)
929.7P/E
30.6EPS
9.32Divi. Yield
0The ANVISA certificate will be valid until May 12, 2027, provided that the applicable GMPs continue to be observed.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 38.75 | 32.71 | 32.67 | 25.02 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -10.8 | -39.96 | -30.48 | -155.67 |
Net Worth | 27.95 | -7.25 | 2.19 | -130.65 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 392.51 | 367.45 | 371.66 | 433.8 |
yoy growth (%) | 6.82 | -1.13 | -14.32 | 2.49 |
Raw materials | -217.14 | -175.73 | -174.09 | -196.97 |
As % of sales | 55.32 | 47.82 | 46.84 | 45.4 |
Employee costs | -64.14 | -67.47 | -87.32 | -87.77 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | -12.4 | -17.96 | -32.36 | 62.4 |
Depreciation | -9.75 | -9.68 | -10.3 | -10.31 |
Tax paid | -0.2 | -0.2 | 0.37 | -0.38 |
Working capital | -11.56 | -7.53 | -58.84 | -73.01 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 6.82 | -1.13 | -14.32 | 2.49 |
Op profit growth | -23.14 | -134.75 | -464.11 | -42.95 |
EBIT growth | -28.4 | -1,016.65 | -101.66 | 294.25 |
Net profit growth | -119.55 | -301.52 | -151.57 | -981.55 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 599.51 | 575.65 | 499.65 | 511.19 | 392.52 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 599.51 | 575.65 | 499.65 | 511.19 | 392.52 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 3.49 | 28.55 | 0.91 | 77.88 | 2.4 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Vice Chairman & Whole Time Dir
K Chandran
Company Sec. & Compli. Officer
Jitendra J Gandhi
Independent Director
Pravin Dilip Pawar
Independent Director
Anupam Vaidya
Whole Time Director
Mohan Kumar Rayana
Independent Director
Mridul Sumanlal Mehta
Additional Director
Pallavur Sankar Dass Vaidyanathan
Additional Director
Manojkumar Khubchand Gursahani
BSEL Tech Park B-Wing 10th Flr,
Sector 30 A Opp Vashi Rly Stat,
Maharashtra - 400703
Tel: 91-22-67942222
Website: http://www.wanbury.com
Email: [email protected]; [email protected]
Unit No 1 Luthra Ind,
Andheri Kurla Road, Safed Pool Andheri(E,
Mumbai - 400 072
Tel: 91-22-2851 5606
Website: www.sharexindia.com
Email: [email protected]
Summary
Wanbury Ltd (Formerly known Pearl Organics Limited) was incorporated in August, 1988. The Company is engaged in the business of pharmaceutical and related activities, including research.The company ha...
Read More
Reports by Wanbury Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.